This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Comparison of Losartan Associated With Indapamide Versus Hyzaar® in the Hypertension Treatment

This study is not yet open for participant recruitment.
See Contacts and Locations
Verified January 2017 by EMS
Information provided by (Responsible Party):
EMS Identifier:
First received: May 29, 2012
Last updated: January 26, 2017
Last verified: January 2017
The purpose of this study is to evaluate the clinical efficacy of indapamide 1.5mg / losartan 50mg and indapamide 1.5mg / losartan 100mg on reduction of blood pressure.

Condition Intervention Phase
Hypertension Drug: Indapamide / Losartan Drug: Hyzaar® Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized, Phase 3, Multicenter, Open Label, Evaluating the Effect of the Treatment of Indapamide 1.5mg/Losartan 50mg and Indapamide 1.5mg/Losartan 100mg, Compared With Hyzaar® in the Treatment of Hypertension

Resource links provided by NLM:

Further study details as provided by EMS:

Primary Outcome Measures:
  • Changes in systemic blood pressure measurements during 12 weeks [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • Safety Will be Evaluated by the Adverse Events Occurrences [ Time Frame: 12 weeks ]

Estimated Enrollment: 636
Anticipated Study Start Date: May 2017
Estimated Study Completion Date: March 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Indapamide 1.5mg / Losartan 50mg Drug: Indapamide / Losartan
1 tablet of Indapamide 1.5mg + Losartan 50mg, oral, a day
Other Name: Indapamide 1.5mg / Losartan 50mg
Experimental: Indapamide 1.5mg / Losartan 100mg Drug: Indapamide / Losartan
1 tablet of Indapamide 1.5mg + Losartan 100mg, oral, a day
Other Name: Indapamide 1.5mg / Losartan 100mg
Active Comparator: Hyzaar® (Losartan 50mg/Hydrochlorothiazide12,5mg) Drug: Hyzaar®
1 tablet of Hyzaar®, oral, a day
Other Name: Losartan 50mg/Hydrochlorothiazide12,5mg
Active Comparator: Hyzaar® (Losartan 100mg/Hydrochlorothiazide 25mg) Drug: Hyzaar®
1 tablet of Hyzaar®, oral, a day
Other Name: Losartan 100mg/Hydrochlorothiazide 25mg

Detailed Description:
  • open label,randomized, multicenter
  • Experiment duration: 12 weeks.
  • 05 visits (day 0 - randomization), (day 1 - 2 weeks pos-randomization), (day 2 - 4 weeks pos-randomization), (day 3 - 8 weeks pos-randomization) and (day 4 - 12 weeks pos-randomization).
  • evaluate the efficacy of a medication associated with two antihypertensive agents in two fixed doses compared to the Hyzaar® in patients with hypertension
  • Adverse events evaluation

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults male or female aged ≥ 18 years old;
  • Patients with a diagnosis of Hypertension (defined by the medical investigator) treated with monotherapy or at least two blood pressure measurements ≥ 140/90, in a sitting position with a 5' interval between measurements,
  • Patients with normal lab tests results in the last six months or that the investigator consider not clinically significant,
  • Patient who accept the discontinuation of previous hypertension therapy.

Exclusion Criteria:

  • Patients with blood pressure ≥ 180/100 mmHg;
  • Patients with uncontrolled hypertension (≥ 140/90 mmHg) treated with thiazide diuretics;
  • Presence of concomitant coronary artery disease, congestive heart failure, diabetes and renal failure (creatinine> 1.5 mg / dL);
  • Patients with hypo or hyperkalemia (serum potassium outside normal range);
  • Patients with ALT greater than 2.5 the upper limit of normal or active liver disease;
  • Pregnant women, or women in childbearing age who are not in use effective contraception or intending to become pregnant during the study period;
  • Patients on drug or alcohol abuse in the last two years;
  • Patients with secondary hypertension (renovascular disease, pheochromocytoma, Cushing's syndrome);
  • Patients with allergic reactions or hypersensitivity to ACE inhibitors, diuretics or medications containing sulfa and / or any excipients of formulation;
  • Refusal or inability to provide the Informed Consent Term.;
  • Refusal to discontinue the anti-hypertensive medication.
  • Patients at the discretion of the investigator does not have indication for discontinuing the current medications;
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01620788

Contact: Roberto B. Amazonas, MD +551938879851

Sponsors and Collaborators
Principal Investigator: Otávio Berwanger, MD Associação do Sanatório Sírio Hosp. do Coração
Principal Investigator: Luiz C. Bodanese, MD União Brasileira de Educação e Assistência / Hospital São Lucas da PUCRS
Principal Investigator: José V. Martin, MD Hospital de Base de São José do Rio Preto
Principal Investigator: Estêvão L. Figueiredo, MD Lifecenter Hospital
Principal Investigator: Renato D. Lopes, M.D Federal University of São Paulo
Principal Investigator: Celso Amodeo, M.D. Instituto Dante Pazzanese de Cardiologia IDPC São Paulo
  More Information

Responsible Party: EMS Identifier: NCT01620788     History of Changes
Other Study ID Numbers: LIEMS1111
Study First Received: May 29, 2012
Last Updated: January 26, 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents
Natriuretic Agents
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Arrhythmia Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists processed this record on September 19, 2017